Sunshine Biopharma, Inc. — FY2021 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended December 31, 2021, with 2020 comparatives; it is an annual report, not a standalone Q4 report. Sunshine Biopharma is a development-stage pharmaceutical and nutritional-supplement company. Its only marketed product was the Essential 9 supplement; all reported revenue came from supplements. Its drug candidates, including Adva-27a and SBFM-PL4, had not entered clinical trials, and the company had made no FDA filings.
Key financial metrics
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $228,426 | $71,410 |
| Cost of sales / gross profit | $117,830 / $110,596 | $25,847 / $45,563 |
| Gross margin | 48.4% | 63.8% |
| General and administrative expenses | $2,550,730 | $622,437 |
| Loss from operations | $(2,440,134) | $(576,874) |
| Net loss per audited financial statements | $(12,436,447), or $(4.76) per share | $(2,784,091), or $(2.73) per share |
| Net cash used in operating activities | $(1,829,128) | $(657,299) |
| Cash and cash equivalents at year-end | $2,045,167 | $989,888 |
At December 31, 2021, current assets were $2,195,830 and current liabilities were $91,229. Total liabilities were $1,991,229, including $1.9 million of long-term notes payable; shareholders’ equity was $211,662. The company reported no income-tax provision and no material off-balance-sheet arrangements.
Changes and unusual items
- Revenue more than tripled year over year, but gross margin declined. G&A rose by approximately $1.93 million; reported R&D expense increased to $672,209 from $1,728.
- The net loss widened substantially, principally reflecting a $9,726,485 loss on debt conversions and $328,818 of interest expense. The filing says 559,144 shares were issued for conversion of debt and interest valued at $12,705,214, reducing debt by $2,867,243 and interest payable by $127,986.
- Cash used in operations increased to $1.83 million. Financing activities provided $2.90 million, mainly from note proceeds. The company reported no cash sale of capital stock during 2021.
- After year-end, the company received approximately $6.8 million net from a February 2022 public offering and approximately $6.8 million net from a March 2022 private placement. It repaid the remaining disclosed notes payable on February 17, 2022. These are subsequent events, not FY2021 results.
Outlook, commentary and risks
- Management estimated that year-end cash plus the two 2022 financings would fund operations for 24 months, including expanded R&D; it cautioned that the estimate may be inaccurate and said additional capital may be needed.
- Adva-27a development had been delayed by insufficient funding. The stated next steps include manufacturing, IND-enabling studies, regulatory filing and Phase I trials, contingent on financing. No clinical or regulatory approvals are assured.
- In December 2021, preliminary mouse-study results indicated two University of Georgia-licensed compounds had no significant effect against SARS-CoV-2; the company said it would discontinue their development. A University of Arizona research agreement on PLpro inhibitors was signed in February 2022.
- Major risks include continued losses, dependence on external financing, clinical and regulatory failure, competition, potential dilution, and dependence on a small team and third-party providers. The company had three employees as of the report date and no product-liability insurance at that time.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2021, citing staffing, accounting, revenue-recognition, inventory and period-end reporting deficiencies. Remediation steps included adding independent directors, establishing an audit committee and planning to hire additional personnel. The auditor did not attest to internal controls.
Important facts for investors to verify
- Net-loss inconsistency: the audited statement of operations reports a 2021 net loss of $12,436,447, while the MD&A and risk-factor text state $12,437,447. Confirm the correct figure and any related per-share presentation.
- Post-year-end liquidity: verify offering and private-placement net proceeds, note repayments, current cash and the assumptions behind management’s 24-month runway estimate.
- Dilution and capitalization: review shares and warrants issued in the 2022 financings, warrant repricing and exercise activity, and the effect of the reverse stock split and preferred-stock voting rights.
- Control remediation: track whether the disclosed material control weaknesses are addressed and whether revenue, inventory and accrual processes improve.
- Pipeline evidence: verify research milestones and data for SBFM-PL4 and Adva-27a, as neither had reached clinical testing and the company’s projected regulatory timelines were expectations, not established guidance.